secwatch / observer
8-K filed July 22, 2024, 7:59 PM ET ticker JANX CIK 0001817713
leadership confidence high sentiment neutral materiality 0.65

Janux Therapeutics board reshuffles: Lichter resigns, Barrett becomes Chair, Hernday and Dobmeier appointed

Janux Therapeutics, Inc.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ron Barrett

Chair of the Board
JANX · Janux Therapeutics, Inc.
Effective
2024-07-19
Filed
July 22, 2024, 7:59 PM ET
In connection with Dr. Lichter’s resignation, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), Ron Barrett, Ph.D. was appointed as Chair of the Board.
Departed

Jay Lichter

Director and Chairman
JANX · Janux Therapeutics, Inc.
Effective
2024-07-19
Successor
Ron Barrett
Filed
July 22, 2024, 7:59 PM ET
On July 19, 2024, Jay Lichter, Ph.D. resigned as a member of the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), including his chairmanship of the Board, effective as of such date.
Appointed

Natasha Hernday

Class II Director
JANX · Janux Therapeutics, Inc.
Effective
2024-07-19
Filed
July 22, 2024, 7:59 PM ET
On July 19, 2024, the Board, upon the recommendation of the Nominating and Governance Committee, appointed (i) Natasha Hernday as a Class II director of the Company, with a term of office expiring at the Company’s 2026 annual meeting of stockholders, or until her earlier death, resignation or removal.
Appointed

Eric Dobmeier

Class III Director
JANX · Janux Therapeutics, Inc.
Effective
2024-07-19
Filed
July 22, 2024, 7:59 PM ET
and (ii) Eric Dobmeier as a Class III director of the Company, with a term of office expiring at the Company’s 2027 annual meeting of stockholders, or until his earlier death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ron Barrett was appointed as Chair of the Board at Janux Therapeutics, Inc..

Action
appointed
Role
Chair of the Board
Exact text from the filing
In connection with Dr. Lichter’s resignation, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), Ron Barrett, Ph.D. was appointed as Chair of the Board.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Jay Lichter resigned as Director and Chairman at Janux Therapeutics, Inc..

Action
resigned
Role
Director and Chairman
Exact text from the filing
On July 19, 2024, Jay Lichter, Ph.D. resigned as a member of the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), including his chairmanship of the Board, effective as of such date.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Natasha Hernday was appointed as Class II Director at Janux Therapeutics, Inc..

Action
appointed
Role
Class II Director
Exact text from the filing
On July 19, 2024, the Board, upon the recommendation of the Nominating and Governance Committee, appointed (i) Natasha Hernday as a Class II director of the Company, with a term of office expiring at the Company’s 2026 annual meeting of stockholders, or until her earlier death, resignation or removal.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Eric Dobmeier was appointed as Class III Director at Janux Therapeutics, Inc..

Action
appointed
Role
Class III Director
Exact text from the filing
and (ii) Eric Dobmeier as a Class III director of the Company, with a term of office expiring at the Company’s 2027 annual meeting of stockholders, or until his earlier death, resignation or removal.
View on SEC.gov

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0000950170-24-085321
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.